{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T02:53:16Z","timestamp":1716000796325},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jurology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.juro.2017.07.071","type":"journal-article","created":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T17:31:15Z","timestamp":1500571875000},"page":"1324-1332","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Outcomes of Chemotherapy Na\u00efve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo"],"prefix":"10.1097","volume":"198","author":[{"given":"Mary-Ellen","family":"Taplin","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Lin","sequence":"additional","affiliation":[{"name":"Medivation, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Krivoshik","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Northbrook, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De","family":"Phung","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Northbrook, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Parli","sequence":"additional","affiliation":[{"name":"Medivation, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[{"name":"Cliniques Universitaires Saint-Luc, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz M.","family":"Beer","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2017.07.071_bib1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.juro.2013.05.005","article-title":"Castration-resistant prostate cancer: AUA guideline","volume":"190","author":"Cookson","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2017.07.071_bib2","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.juro.2017.07.071_bib3","first-page":"707","article-title":"Clinical phenotypes of castration-resistant prostate cancer","volume":"11","author":"Zhang","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.juro.2017.07.071_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0090-4295(99)00471-9","article-title":"Clinical states in prostate cancer: toward a dynamic model of disease progression","volume":"55","author":"Scher","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.juro.2017.07.071_bib5","doi-asserted-by":"crossref","first-page":"8253","DOI":"10.1200\/JCO.2005.03.4777","article-title":"Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis","volume":"23","author":"Scher","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2017.07.071_bib6","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","article-title":"Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers","volume":"22","author":"Aparicio","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2017.07.071_bib7","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.juro.2017.07.071_bib8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2017.07.071_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2017.02.007","article-title":"Effect of visceral disease site on outcomes in patients with metastatic castration-resistant prostate cancer treated with enzalutamide in the PREVAIL Trial","author":"Alumkal","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.juro.2017.07.071_bib10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2016.03.017","article-title":"The PREVAIL study: primary outcomes by site and extent of baseline disease for enzalutamide-treated men with chemotherapy-naive metastatic castration-resistant prostate cancer","volume":"70","author":"Evans","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.07.071_bib11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000020289","article-title":"Low PSA metastatic androgen-independent prostate cancer","volume":"38","author":"Sella","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.07.071_bib12","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1158\/1078-0432.CCR-07-1036","article-title":"A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis","volume":"13","author":"Armstrong","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2017.07.071_bib13","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2003.06.100","article-title":"Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer","volume":"21","author":"Halabi","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.juro.2017.07.071_bib14","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1200\/JCO.2002.11.021","article-title":"Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration","volume":"20","author":"Smaletz","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.juro.2017.07.071_bib15","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","article-title":"Aggressive variants of castration-resistant prostate cancer","volume":"20","author":"Beltran","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2017.07.071_bib16","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1200\/JCO.2011.39.1300","article-title":"Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer","volume":"30","author":"Nelson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2017.07.071_bib17","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMe1409306","article-title":"Targeting the androgen receptor in prostate cancer\u2014a resilient foe","volume":"371","author":"Nelson","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002253471777187X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002253471777187X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2017.07.071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T05:08:57Z","timestamp":1651208937000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2017.07.071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1016\/j.juro.2017.07.071"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2017.07.071","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes of Chemotherapy Na\u00efve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo","name":"articletitle","label":"Article Title"},{"value":"The Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.juro.2017.07.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.","name":"copyright","label":"Copyright"}]}}